Publikasi Scopus 2023 per tanggal 30 April 2023 (283 artikel)

Büchler A.C., Shahab S.N., Severin J.A., Vos M.C., Voor in ’t holt A.F.
57215741418;58076961800;8700385500;57221445308;57202387807;
Outbreak investigations after identifying carbapenem-resistant Pseudomonas aeruginosa: a systematic review
2023
Antimicrobial Resistance and Infection Control
12
1
28
Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, Netherlands; Department of Clinical Microbiology, Dr. Cipto Mangunkusumo General Hospital - Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Büchler, A.C., Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, Netherlands; Shahab, S.N., Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, Netherlands, Department of Clinical Microbiology, Dr. Cipto Mangunkusumo General Hospital - Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Severin, J.A., Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, Netherlands; Vos, M.C., Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, Netherlands; Voor in ’t holt, A.F., Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, Netherlands
Background: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are a serious cause of healthcare-associated infections. Part of the infection prevention and control measures are outbreak investigations (OI) of patients, healthcare workers (HCW), and the environment after identifying a CRPA in order to identify carriers and environmental reservoirs, so that targeted actions can be taken to prevent further transmission. However, little is known on when and how to perform such OI. Therefore, this systematic review aims to summarize OI performed after detection of CRPA in the endemic and epidemic hospital setting. Main text: Articles related to our research question were identified through a literature research in multiple databases (Embase, Medline Ovid, Cochrane, Scopus, Cinahl, Web of Science, and Google Scholar) until January 12, 2022 (Prospero registration number CRD42020194165). Hundred-twenty-six studies were included. In both the endemic and the epidemic setting, a median number of two out of seven predefined components of OI were identified. In the endemic setting, the most frequent component of OI was screening of the environment (28 studies, 62.2%). In the epidemic setting, screening of the environment (72 studies, 88.9%), and screening of patients during hospitalization (30 studies, 37%) were most frequently performed. Only 19 out of 126 studies (15.1%) reported screening of contact patients, and 37 studies reported screening of healthcare workers (HCW, 29.4%). Conclusion: Due to probable underreporting of OI in the literature, the available evidence for the usefulness of the individual components of OI is scarce. This could lead to inhomogeneous performance of OI after detection of CRPA in the healthcare setting, and with this, potential under- or overscreening. While we could show evidence for the usefulness for environmental screening in order to identify the mode of transmission, evidence for HCW screening is scarce and might not lead to the identification of modes of transmission. Further studies are needed to better understand CI in different settings and, finally, develop guidance on when and how to best perform OI. © 2023, The Author(s).
Bacterial drug resistance; Infection control; Outbreak investigations; Pseudomonas aeruginosa; Systematic review
antiinfective agent; carbapenem derivative; epidemic; genetics; human; Pseudomonas aeruginosa; risk factor; Anti-Bacterial Agents; Carbapenems; Disease Outbreaks; Humans; Pseudomonas aeruginosa; Risk Factors
Universität Basel
This work was supported by a personal grant to Andrea C. Büchler by the Forschungsfonds of the University of Basel, Basel, Switzerland. The funding source had no role in the design, analysis or results of the study.
BioMed Central Ltd
20472994
37013661
Review
Q1
1286
2738